Equity Research Biotechnology

Should You Buy Oramed Pharmaceuticals Inc. Stock in 2026?

By CirclFi Research Team · · Updated · 4/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Oramed Pharmaceuticals Inc. (ORMP) occupies a solid middle-ground position with a Quality of Company score of 6.3/10. At the current market price of $4.62, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.

The short answer: 4 of 4 CirclFi valuation models project upside for Oramed Pharmaceuticals Inc. (ORMP) at $4.62 — the model consensus leans bullish, with a Quality Score of 6.3/10 and Value-Trap risk of 39/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 4 of 4 models see upside — majority bullish
  • Quality Score: 6.3/10 — Moderate — mixed signals
  • Value Trap Risk: 39/100 — Low — manageable risk
  • Fair Value Range: $6.77 – $13.31 (96% spread)

Bullish Models

4 / 4

Bearish Models

0 / 4

Quality Score

6.3 /10

Moderate — mixed signals

Value Trap Risk

39 /100
Low

Low — manageable risk

Model Consensus

4 /13
Active Models

Avg. confidence: 16%

What Is the Investment Case for Oramed Pharmaceuticals Inc. (ORMP) in 2026?

What Is the Bull Case vs the Bear Case for Oramed Pharmaceuticals Inc. (ORMP)?

Bull case versus bear case for Oramed Pharmaceuticals Inc. (ORMP) at $4.62, derived from 4 active CirclFi valuation models on 2026-09-15.
Bull case — $13.31 target (+188.1%) Bear case
According to the CirclFi Deep Alpha Valuation Engine, 4 of 4 models identify upside from $4.62 to a median fair value of $9.56, indicating the market hasn't fully priced in Oramed Pharmaceuticals Inc.'s earnings power. No active model flags significant downside for ORMP. The Value Trap score of 39/100 still argues for some caution.
According to the CirclFi Deep Alpha Valuation Engine, the CUCE model targets a fair value of $13.31 (+188.1%), anchoring the bull case with a methodology that provides a differentiated analytical lens.
Industry tailwind: partnership and licensing deals could provide meaningful support for Oramed Pharmaceuticals Inc.'s revenue and margin trajectory in the Biotechnology space.

How Does ORMP Compare to Its Biotechnology Peers?

CTMX CytomX Therapeutics,
6.3
SEPN Septerna, Inc.
6.3
QURE uniQure N.V.
6.3
RLYB Rallybio Corporation
6.3
ASMB Assembly Biosciences
6.3
VTGN Vistagen Therapeutic
6.3
CBUS Cibus, Inc.
5.2
VERA Vera Therapeutics, I
4.6

Valuation data pages: CTMX · SEPN · QURE · RLYB · ASMB · VTGN · CBUS · VERA · CNXU · EXEL · INCY

See full Biotechnology rankings →

Which Other Stocks Score Like ORMP on Quality?

Closest companies to ORMP’s Quality of Company score of 6.3/10, across all industries.

Which Biotechnology Screens Does ORMP Appear In?

Why Do CirclFi’s 4 Models Disagree on ORMP?

Spread

96%

Fair Value Range

$6.77 – $13.31

A 96% spread represents moderate disagreement. The models agree on direction but differ on magnitude.

Most Bullish

CUCE

$13.31 (+188.1%)

Most Bearish

Regime Cross

$6.77 (+46.6%)

What Are the Biggest Risks of Buying ORMP Stock?

Macro/Sector Risk

Biotechnology headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View ORMP Data Page →

So Is Oramed Pharmaceuticals Inc. (ORMP) Worth Buying in 2026?

The convergence of 6.3/10 quality, multi-model undervaluation (4/4 bullish, +106.9% median upside), and a median fair value of $9.56 vs. $4.62 current price makes Oramed Pharmaceuticals Inc. one of the more compelling opportunities in our coverage. As always, our models provide a quantitative starting point — not a substitute for individual due diligence.

These are quantitative model outputs, not investment recommendations. Oramed Pharmaceuticals Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About ORMP Stock?

Should I buy ORMP stock right now?

Based on CirclFi's multi-model analysis, 4 of 4 models see upside for ORMP at $4.62. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 6.3/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Oramed Pharmaceuticals Inc.?

Key risks include: limited model coverage (4/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.

How does ORMP compare to its competitors?

Among Biotechnology peers, ORMP holds a Quality Score of 6.3/10. Comparable companies include CTMX (QOC 6.3), SEPN (QOC 6.3), QURE (QOC 6.3). The relative ranking helps investors identify whether ORMP offers better fundamental quality than alternatives in the same sector.

Is ORMP a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ORMP's Quality Score of 6.3/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.

What price should I buy ORMP at?

CirclFi does not provide target buy prices or price alerts. However, our 4 active models produce fair value estimates ranging from $6.77 to $13.31. At $4.62, the stock trades below even the most conservative estimate, which may represent a margin of safety — or reflect risks the models don't capture. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for ORMP.

View ORMP Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →